CL2018000462A1 - Conjugados de aldehído y usos de los mismos. - Google Patents
Conjugados de aldehído y usos de los mismos.Info
- Publication number
- CL2018000462A1 CL2018000462A1 CL2018000462A CL2018000462A CL2018000462A1 CL 2018000462 A1 CL2018000462 A1 CL 2018000462A1 CL 2018000462 A CL2018000462 A CL 2018000462A CL 2018000462 A CL2018000462 A CL 2018000462A CL 2018000462 A1 CL2018000462 A1 CL 2018000462A1
- Authority
- CL
- Chile
- Prior art keywords
- aldehyde
- hne
- mda
- implicated
- neurological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
La presente invención proporciona compuestos y métodos de uso de los mismos para tratar, prevenir y/o reducir el riesgo de enfermedad, trastorno o condición en el cual la toxicidad por aldehído está implicada en la patogénesis incluyendo trastornos oculares, dérmicos, condiciones asociadas a los efectos dañinos de agentes ampollantes, y enfermedades autoinmunes, inflamatorias, neurológicas y cardiovasculares mediante el uso de una amina primaria para secuestrar aldehídos tóxicos, como MDA y HNE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562208278P | 2015-08-21 | 2015-08-21 | |
US201662315455P | 2016-03-30 | 2016-03-30 | |
US201662347464P | 2016-06-08 | 2016-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000462A1 true CL2018000462A1 (es) | 2018-08-17 |
Family
ID=58100899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000462A CL2018000462A1 (es) | 2015-08-21 | 2018-02-21 | Conjugados de aldehído y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20180250306A1 (es) |
EP (1) | EP3337470A4 (es) |
JP (2) | JP6959650B2 (es) |
KR (1) | KR20180073553A (es) |
CN (2) | CN108135867A (es) |
AU (1) | AU2016311163A1 (es) |
BR (1) | BR112018003264A2 (es) |
CA (1) | CA2996186A1 (es) |
CL (1) | CL2018000462A1 (es) |
CO (1) | CO2018002841A2 (es) |
HK (1) | HK1256143A1 (es) |
IL (1) | IL257615A (es) |
MX (1) | MX2018002157A (es) |
WO (1) | WO2017035082A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2393768T3 (es) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Derivado de quinolina para el tratamiento de enfermedades retinianas |
KR102435676B1 (ko) | 2013-01-23 | 2022-08-24 | 알데이라 테라퓨틱스, 아이엔씨. | 독성 알데히드 관련된 질병 및 치료 |
JP6947406B2 (ja) * | 2015-08-21 | 2021-10-13 | アルデイラ セラピューティクス, インコーポレイテッド | 重水素化化合物およびその使用 |
CN116531400A (zh) | 2016-02-28 | 2023-08-04 | 奥尔德拉医疗公司 | 用环糊精治疗过敏性眼部病状 |
CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
EP3500256A4 (en) * | 2016-08-22 | 2020-01-08 | Aldeyra Therapeutics, Inc. | ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF |
US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
US20220017475A1 (en) | 2018-08-06 | 2022-01-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
CA3113462A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
US20220133697A1 (en) * | 2018-12-05 | 2022-05-05 | Aldeyra Therapeutics, Inc. | Injectable formulations |
CN113227051B (zh) * | 2018-12-18 | 2022-05-17 | 南京明德新药研发有限公司 | 用于视网膜疾病的化合物 |
US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
CA3159453A1 (en) * | 2019-12-30 | 2021-07-08 | Huijun YIN | Tricyclic compound, and preparation method therefor and medical use thereof |
EP4135697A4 (en) * | 2020-04-13 | 2024-05-15 | Aldeyra Therapeutics Inc | QUINOLINE COMPOUNDS FOR THE TREATMENT OF LUNG, LIVER AND KIDNEY DISEASES, CONDITIONS OR AFFECTIONS |
WO2021254456A1 (zh) * | 2020-06-17 | 2021-12-23 | 南京明德新药研发有限公司 | 2-甲基2-丙醇和氨基取代的芳基化合物的晶型 |
WO2021254453A1 (zh) * | 2020-06-17 | 2021-12-23 | 南京明德新药研发有限公司 | 氨基吡啶类化合物 |
CN116406263A (zh) * | 2020-09-28 | 2023-07-07 | 珠海联邦制药股份有限公司 | 吡啶苯基类化合物的晶型及其制备方法 |
KR20230128056A (ko) * | 2020-12-29 | 2023-09-01 | 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 | 삼환식 화합물, 및 그의 제조 방법 및 그의 의학적용도 |
WO2022267930A1 (zh) * | 2021-06-25 | 2022-12-29 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
ES2393768T3 (es) * | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Derivado de quinolina para el tratamiento de enfermedades retinianas |
JP5793459B2 (ja) * | 2012-03-30 | 2015-10-14 | 新日鐵住金ステンレス株式会社 | 加工性に優れた耐熱フェライト系ステンレス冷延鋼板、冷延素材用フェライト系ステンレス熱延鋼板及びそれらの製造方法 |
EP2935220A4 (en) * | 2012-12-20 | 2016-04-27 | Aldeyra Therapeutics Inc | PERI-carbinol |
KR102435676B1 (ko) * | 2013-01-23 | 2022-08-24 | 알데이라 테라퓨틱스, 아이엔씨. | 독성 알데히드 관련된 질병 및 치료 |
-
2016
- 2016-08-22 WO PCT/US2016/048064 patent/WO2017035082A1/en active Application Filing
- 2016-08-22 EP EP16839946.7A patent/EP3337470A4/en not_active Withdrawn
- 2016-08-22 BR BR112018003264A patent/BR112018003264A2/pt not_active Application Discontinuation
- 2016-08-22 MX MX2018002157A patent/MX2018002157A/es unknown
- 2016-08-22 CN CN201680059226.6A patent/CN108135867A/zh active Pending
- 2016-08-22 AU AU2016311163A patent/AU2016311163A1/en not_active Abandoned
- 2016-08-22 KR KR1020187008120A patent/KR20180073553A/ko not_active Application Discontinuation
- 2016-08-22 CA CA2996186A patent/CA2996186A1/en active Pending
- 2016-08-22 US US15/754,163 patent/US20180250306A1/en not_active Abandoned
- 2016-08-22 JP JP2018509770A patent/JP6959650B2/ja active Active
- 2016-08-22 CN CN202111347099.9A patent/CN114085236A/zh active Pending
-
2018
- 2018-02-19 IL IL257615A patent/IL257615A/en unknown
- 2018-02-21 CL CL2018000462A patent/CL2018000462A1/es unknown
- 2018-03-16 CO CONC2018/0002841A patent/CO2018002841A2/es unknown
- 2018-11-28 HK HK18115224.6A patent/HK1256143A1/zh unknown
-
2019
- 2019-10-03 US US16/592,572 patent/US20200246345A1/en not_active Abandoned
-
2021
- 2021-04-13 US US17/229,797 patent/US20220354857A1/en active Pending
- 2021-10-01 JP JP2021162736A patent/JP7332186B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20220354857A1 (en) | 2022-11-10 |
JP2018530524A (ja) | 2018-10-18 |
CA2996186A1 (en) | 2017-03-02 |
CO2018002841A2 (es) | 2018-07-10 |
MX2018002157A (es) | 2018-06-08 |
JP2022000469A (ja) | 2022-01-04 |
WO2017035082A1 (en) | 2017-03-02 |
CN108135867A (zh) | 2018-06-08 |
BR112018003264A2 (pt) | 2018-09-25 |
EP3337470A1 (en) | 2018-06-27 |
JP7332186B2 (ja) | 2023-08-23 |
EP3337470A4 (en) | 2019-02-27 |
IL257615A (en) | 2018-04-30 |
CN114085236A (zh) | 2022-02-25 |
US20180250306A1 (en) | 2018-09-06 |
HK1256143A1 (zh) | 2019-09-13 |
AU2016311163A1 (en) | 2018-04-05 |
US20200246345A1 (en) | 2020-08-06 |
KR20180073553A (ko) | 2018-07-02 |
JP6959650B2 (ja) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018002841A2 (es) | Conjugados de aldehído y usos de los mismos | |
CO2019001625A2 (es) | Compuestos de captura de aldehído y usos de los mismos | |
CL2018000463A1 (es) | Compuestos deuterados y usos de los mismos | |
MX2019012878A (es) | Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido. | |
GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CO2019005236A2 (es) | Métodos para tratar afecciones inflamatorias | |
BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
CL2019000230A1 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos. | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
CL2017000290A1 (es) | Inhibidores de la proteína kinasa c y métodos de su uso. | |
CL2017002719A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
CR20150496A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
ECSP16082599A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. | |
CL2018003013A1 (es) | Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. | |
ECSP15011105A (es) | siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES |